Lb Pharmaceuticals (LBRX) Assets Average (2025 - 2026)
Lb Pharmaceuticals (LBRX) posted quarterly Assets Average of $353.2 million for Q1 2026, up 11.48% quarter-over-quarter from $316.8 million in Q4 2025.
Powered by 
Analysis
Lb Pharmaceuticals (LBRX) Assets Average (2025 - 2026) Analysis & Trends
Lb Pharmaceuticals' Assets Average history runs 2 years deep, the most recent figure standing at $353.2 million for Q1 2026.
- In Q1 2026, Assets Average changed N/A year-over-year to $353.2 million; the TTM figure through Mar 2026 stood at $353.2 million (changed N/A YoY), while the FY2025 annual figure was $173.2 million, changed N/A from the prior year.
- Assets Average for Q1 2026 stood at $353.2 million, up from $316.8 million in the prior quarter.
- The five-year high for Assets Average was $353.2 million in Q1 2026, with the low at $316.8 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 11.22 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 3.29 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.86 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 5.34 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.82 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Lb Pharmaceuticals | 1.49 Bn | 1.49 Bn | - | 377.59 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 377.59 Mn |
| Mar 31, 2026 | 353.21 Mn |
| Dec 31, 2025 | 316.84 Mn |